Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval in dogs.
-
- IWAMOTO Ken-ichiro
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
-
- IKEDA Jun-ichi
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
-
- NITO Masaaki
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
-
- KOSAKA Nobuo
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
-
- ICHIKAWA Shunji
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
-
- KOBAYASHI Hiroyuki
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
-
- OHMORI Kenji
- Pharmaceutical Research Laboratories, Kyowa Hako Kogyo Co., Ltd.
Bibliographic Information
- Other Title
-
- 新規抗アレルギー薬塩酸オロパタジンのイヌ心電図QT間隔に対する作用
- シンキ コウアレルギーヤク エンサン オロパタジン ノ イヌ シンデンズ QT カンカク ニ タイスル サヨウ
- Effect of olopatadine hydrochloride, a novel antiallergic agent, on the QT interval
Search this article
Abstract
Olopatadine hydrochloride (olopatadine), a novel antiallergic agent, is effective in the treatment of allergic rhinitis, chronic urticaria, eczema and dermatitis. It has been reported that terfenadine and astemizole cause side effects on the circulatory system such as QT prolongation followed by serious ventricular arrhythmias (torsades de pointes). To investigate the possibility of QT prolongation, we used both conscious normal dogs and hypokalemia-anesthetized dogs under two conditions: 1) olopatadine used alone and 2) olopatadine used in combination with itraconazole, the CYP3A4-inhibiting antifungal agent, in the present investigation. The group treated with terfenadine alone (30 mg/kg, p.o.) and the group treated with a combination of terfenadine (10 mg/kg, p.o.) and itraconazole (100 mg/kg, p.o.) had a significantly prolonged QT interval. On the other hand, the group treated with olopatadine alone (30 mg/kg, p.o.) and the group treated with a combination of olopatadine (30 mg/kg, p.o.) and itraconazole (100 mg/kg, p.o.) did not show any significant changes in QT interval. Moreover, olopatadine (1 and 5 mg/kg, i.v.) did not influence the QT interval in hypokalemia-anesthetized dogs. These results suggest that there is very little possibility of QT prolongation as a result of clinically used olopatadine.
Journal
-
- Folia Pharmacologica Japonica
-
Folia Pharmacologica Japonica 117 (6), 401-409, 2001
The Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390001204271404544
-
- NII Article ID
- 10007366485
-
- NII Book ID
- AN00198335
-
- COI
- 1:CAS:528:DC%2BD3MXktVygsr8%3D
-
- ISSN
- 13478397
- 00155691
-
- NDL BIB ID
- 5776705
-
- PubMed
- 11436518
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed